Show simple item record

dc.contributor.authorKaratas, A.
dc.contributor.authorYalcinkaya, YASEMİN
dc.contributor.authorCan, G.
dc.contributor.authorPehlivan, Y.
dc.contributor.authorTufan, A.
dc.contributor.authorYAZICI, AYTEN
dc.contributor.authorÇEFLE, AYŞE
dc.contributor.authorAkar, S.
dc.contributor.authorSenel, S.
dc.contributor.authorOz, B.
dc.contributor.authorAKKOC, N.
dc.contributor.authorOnen, F.
dc.contributor.authorInanc, N.
dc.contributor.authorOzen, G.
dc.contributor.authorDalkilic, E.
dc.contributor.authorKoca, S. S.
dc.date.accessioned2021-03-05T15:55:35Z
dc.date.available2021-03-05T15:55:35Z
dc.identifier.citationInanc N., Ozen G., Yalcinkaya Y., Dalkilic E., Koca S. S. , Can G., Karatas A., Pehlivan Y., YAZICI A., ÇEFLE A., et al., "IS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?", Congress of the European-League-Against-Rheumatism (EULAR), Amsterdam, Hollanda, 13 - 16 Haziran 2018, cilt.77, ss.611-612
dc.identifier.othervv_1032021
dc.identifier.otherav_be23e585-ed6e-408d-ba24-fd951aa45ea1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/126305
dc.identifier.urihttps://doi.org/10.1136/annrheumdis-2018-eular.5662
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectİmmünoloji ve Romatoloji
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectKlinik Tıp
dc.subjectROMATOLOJİ
dc.titleIS THERE ANY DIFFERENCE IN RA PATIENTS FOR METHOTREXATE USE VS. LEFLUNOMIDE USE AS A CONCOMITANT TREATMENT WITH BIOLOGICAL AND TARGETED SYNTHETIC DMARDS IN TURKBIO REGISTRY?
dc.typeBildiri
dc.contributor.departmentKocaeli Üniversitesi , Tıp Fakültesi , Dahili Tıp Bilimleri
dc.identifier.volume77
dc.contributor.firstauthorID104951


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record